Literature DB >> 1975258

Prevention by silymarin of membrane alterations in acute CCl4 liver damage.

P Muriel1, M Mourelle.   

Abstract

The effect of silymarin on liver lipid peroxidation and membrane lipid alterations induced by an acute dose of CCl4 was studied. Four groups of animals were treated with CCl4, CCl4 + silymarin, silymarin and its vehicles. CCl4 was given orally (0.4 g 100 g-1 body wt.) and silymarin was administered i.p. All animals were sacrificed 24 h after the treatments. Liver lipid peroxidation was measured and plasma membranes were isolated. Alkaline phosphatase (AP) and gamma-glutamyl transpeptidase (GGTP) were measured in plasma membranes. Membrane lipids were extracted and then analysed by thin-layer chromatography by measuring the phosphorus of the phospholipids in each spot. Liver lipid peroxidation was increased about three times in the group receiving CCl4 only. Silymarin cotreatment prevented this increase. Phosphatidylethanolamine (PEA) decreased, while phosphatidylinositol (PI) increased in the plasma membranes isolated from the CCl4-treated group. Animals that received CCl4 + silymarin showed no decrease in PEA content. A partial prevention of the decrease in phosphatidylinositol content was also observed in plasma membranes of animals treated with silymarin in addition to CCl4. CCl4 decreased gamma-glutamyl transpeptidase (GGTP) and alkaline phosphatase (AP) membrane activities. Silymarin cotreatment prevented the AP (completely) and the GGTP (partially) falls caused by CCl4. Silymarin by itself increased AP membrane activity. A significant relationship between the membrane content of phosphatidylethanolamine (PEA) and the AP activity was observed in plasma membranes of treated animals and in normal liver membranes enriched with PEA. These results indicate that silymarin can protect against the alterations induced by CCl4 on the liver plasma membrane through its antioxidant properties by modifying the plasma membrane phospholipid content.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975258     DOI: 10.1002/jat.2550100408

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  25 in total

1.  The protective effect of silymarin on the carbon tetrachloride (CCl4)-induced liver injury in common carp (Cyprinus carpio).

Authors:  Rui Jia; Liping Cao; Jinliang Du; Pao Xu; Galina Jeney; Guojun Yin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2013-02-22       Impact factor: 2.416

Review 2.  Is there any use for nontraditional or alternative therapies in patients with chronic liver disease?

Authors:  N M Bass
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  In vitro hepatoprotective and antioxidant activities of crude extract and isolated compounds from Ficus gnaphalocarpa.

Authors:  Donfack J Hubert; Amadou Dawe; Ngueguim T Florence; Kapche D W F Gilbert; Tchana N Angele; D Buonocore; P Vita Finzi; G Vidari; Ngadjui T Bonaventure; Fulvio Marzatico; Moundipa F Paul
Journal:  Inflammopharmacology       Date:  2010-11-19       Impact factor: 4.473

4.  Assessment of the Antioxidant Activity of Silybum marianum Seed Extract and Its Protective Effect against DNA Oxidation, Protein Damage and Lipid Peroxidation.

Authors:  Aynur Serçe; Bircan Çeken Toptancı; Sevil Emen Tanrıkut; Sevcan Altaş; Göksel Kızıl; Süleyman Kızıl; Murat Kızıl
Journal:  Food Technol Biotechnol       Date:  2016-12       Impact factor: 3.918

5.  Silibinin pretreatment protects against ochratoxin A-mediated apoptosis in primary rat hepatocytes.

Authors:  E Essid; E Petzinger
Journal:  Mycotoxin Res       Date:  2011-04-19       Impact factor: 3.833

6.  Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.

Authors:  Omar Mohamed E Abdel Salam; Amany A Sleem; Nermeen Shafee
Journal:  Inflammopharmacology       Date:  2010-01-14       Impact factor: 4.473

Review 7.  Antioxidants in liver health.

Authors:  Sael Casas-Grajales; Pablo Muriel
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-08-06

8.  Effects of silymarin and pentoxifylline on matrix metalloproteinase-1 and -2 expression and apoptosis in experimental hepatic fibrosis.

Authors:  Eray Kara; Teoman Coşkun; Yavuz Kaya; Okan Yumuş; Seda Vatansever; Ahmet Var
Journal:  Curr Ther Res Clin Exp       Date:  2008-12

9.  A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.

Authors:  Samer S El-Kamary; Michelle D Shardell; Mohamed Abdel-Hamid; Soheir Ismail; Mohamed El-Ateek; Mohamed Metwally; Nabiel Mikhail; Mohamed Hashem; Amr Mousa; Amr Aboul-Fotouh; Mohamed El-Kassas; Gamal Esmat; G Thomas Strickland
Journal:  Phytomedicine       Date:  2009-03-19       Impact factor: 5.340

10.  Herbal Supplement Ameliorates Cardiac Hypertrophy in Rats with CCl(4)-Induced Liver Cirrhosis.

Authors:  Ping-Chun Li; Yung-Wei Chiu; Yueh-Min Lin; Cecilia Hsuan Day; Guang-Yuh Hwang; Peiying Pai; Fuu-Jen Tsai; Chang-Hai Tsai; Yu-Chun Kuo; Hsiao-Chuan Chang; Jer-Yuh Liu; Chih-Yang Huang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-06       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.